Clinical trials: Renal Dysfunction
Peritoneal Dialysis Associated Peritonitis
Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis
Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent peritonitis remains the major cause of peritoneal…
- Trial name
- NCT01817309
- Testing
- endotoxin assay in peritoneal dialysis effluent
- Where
- Hong Kong
- Volunteers
- 325 people
- Sponsor
- Chinese University of Hong Kong
Chronic Kidney Disease, Chronic Hepatitis C
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
- Trial name
- NCT02946034
- Testing
- Viekira Pak ± ribavirin, Mavyret
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Chronic Renal Disease
Urotensin II in Chronic Kidney Diseases and Kidney Transplants
The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.
- Trial name
- NCT01098799
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Vakif Gureba Training and Research Hospital
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Healthy Volunteers, Renal Impairment
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)
The purpose of this study is to characterize the effect of renal function on the plasma, urine, and dialysate pharmacokinetic profile of MK-6183 (CB-238,618) in humans.
- Trial name
- NCT02341599
- Testing
- MK-6183
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Kidney Injury
Acute Kidney Injury Standardized Clinical Assessment and Management Plan for Renal Replacement Initiation
This study is of a clinical decision support tool for clinicians taking care of patients with severe acute kidney injury in the intensive care unit.
- Trial name
- NCT03368183
- Testing
- Care delivery algorithim
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-1 (NCT05832931)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 362 people
- Sponsor
- Pathalys Pharma
End Stage Renal Disease, End-Stage Kidney Disease
Prognostic Value of Finger Blood Pressure in Arteriovenous Fistula Care
The goal of this trial is to investigate the prognostic value of monitoring finger blood pressures (FBPs) in predicting the success of surgically created arteriovenous fistula (AVF) for patients with end stage renal disease.
- Conditions
- End Stage Renal Disease, End-Stage Kidney Disease, Dialysis Access Dysfunction
- Trial name
- NCT06765577
- Testing
- Finger Blood Pressure Measurement
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore General Hospital
Acute Coronary Syndrome, Renal Insufficiency
Remote Ischemic Preconditioning in ACS Patients
Remote ischemic preconditioning is a process of serial blood pressure cuff inflations and deflations that are performed prior to a procedure and have been shown in various other areas (coronary bypass surgery, vascular surgery…
- Conditions
- Acute Coronary Syndrome, Renal Insufficiency, Ischemia, Myocardial
- Trial name
- NCT03329612
- Testing
- Remote Ischemic Preconditioning
- Where
- United States
- Sponsor
- Henry Ford Health System
Renal Insufficiency, Chronic, Inflammation
Effects of Cranberry Supplementation on Chronic Kidney Disease Patients.
Patients with chronic kidney disease (CKD) have several complications that are linked to oxidative stress and inflammation, and among the most recently studied is the alteration of the intestinal microbiota.
- Conditions
- Renal Insufficiency, Chronic, Inflammation, Oxidative Stress, Gastrointestinal Microbiome
- Trial name
- NCT04377919
- Testing
- Cranberry
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universidade Federal Fluminense
Chronic Kidney Diseases
Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach
Nephrology care continues to progress and recommendations are now focused on delaying as much as possible the need for renal replacement therapy ("intent-to-defer"strategy).
- Trial name
- ProReRePro (NCT03979534)
- Testing
- low protein diet
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier le Mans
Delirium, Acute Kidney Injury
Neurocognitive Outcomes for ICU Patients With Acute Kidney Injury
Introduction. Initiation of acute kidney replacement therapy (KRT) is common in critically ill adults admitted to the intensive care unit (ICU), and is associated with increased morbidity and mortality.
- Conditions
- Delirium, Acute Kidney Injury, Critical Illness, Cognitive Impairment
- Trial name
- INCOGNITOAKI (NCT04722939)
- Testing
- Cerebral oxygenation
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- Dr. Gordon Boyd
Hyperkalemia, Heart Failure
Evaluation of Patiromer in Heart Failure Patients
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
- Trial name
- PEARL-HF (NCT00868439)
- Testing
- patiromer
- Where
- 33 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Relypsa, Inc.
Normal Renal Function, Mildly Impaired Renal Function
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
- Conditions
- Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
- Trial name
- NCT00543075
- Testing
- Genasense (oblimersen, G3139)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Genta Incorporated
Morbid Obesity, Chronic Kidney Disease (Stage 3-4)
Metabolic Status and Risk of Chronic Kidney Disease in French Overseas Populations With Morbid Obesity (OBECAMcohort).
Morbid obesity is defined by a body mass index (BMI) ≥ 40 kg/m2 or > 35 if there is at least one comorbidity (hypertension, diabetes, hypercholesterolemia, joint pain, obstructive sleep apnea syndrome, etc.) Morbid obesity…
- Trial name
- OBECAMcohort (NCT07830030)
- Where
- Guadeloupe
- Volunteers
- 480 people
- Sponsor
- Clinique
End-Stage Kidney Disease, Hemodialysis
A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients with Hemodialysis
The high mortality rate and costs of patients with end-stage renal disease (ESRD) are a medical and socio-economic burden, so managing their risk factors is very important.
- Trial name
- NCT06688565
- Testing
- Hativ® electrocardiogram monitoring
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Hallym University Medical Center
Chronic Kidney Diseases, Acute Coronary Syndrome
Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD
To compare clinical outcomes in patients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) treated with clopidogrel or ticagrelor (both FDA approved and guideline indicated drugs for treating…
- Trial name
- CPRS-CKD (NCT03150667)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- North Texas Veterans Healthcare System
Diabetes Mellitus, Chronic Kidney Diseases
Cardiometabolic Devices Accuracy Study
With the rise of cardiovascular diseases (CVD) and diabetes, the global disease burden is shifting towards non-communicable diseases (NCDs).
- Conditions
- Diabetes Mellitus, Chronic Kidney Diseases, Hyperlipidemias
- Trial name
- NCT05257564
- Testing
- Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)
- Where
- Nepal
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Chronic Hepatitis C, End Stage Renal Disease
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
The treatment response with conventional interferon alpha alone in patients with end stage renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is 17-29.6%.
- Trial name
- NCT00172809
- Testing
- Peginterferon alfa-2a, Interferon alfa-2a
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.